Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular ...

Drew Carey, MD, and Andrew G. Lee, MD, discuss triage, visual fields, double vision, and cataract topics from ...

Mark J. Gallardo, MD, discusses how the laser performed alongside cataract surgery in open-angle glaucoma, including ...

At AAO 2026 Retina Subspecialty Day, SriniVas Sadda, MD, outlined limits of current GA growth metrics and introduced border ...

Oral PKC inhibitor darovasertib preserved the eye in 57% of patients facing enucleation and cut projected radiation doses in ...

The concerns of October 10, 1857, sound remarkably familiar today.

Noguchi FS formula error was 0.280 D in 486 eyes, LAL piggyback cut residual cylinder to 0.1 D, and Yamane and Gore-Tex fixation showed distinct complication profiles.

Teprotumumab N01 injection (SYCUME, IBI311; Innovent Biologics) met the primary end point of the phase 3 RESTORE-3 trial in inactive thyroid eye disease, according to a company announcement.¹ At week ...

Keith Warren, MD | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology Times, Modern ...

At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, ...

The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...

Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal ...